Key result
Mycophenolate mofetil controls recurrent myocarditis driven by a novel DSP variant in a teen.
Why the study?
Recurrent myocarditis can result from genetic mutations like desmoplakin (DSP), where accurate genetic diagnosis is essential for proper management.
Does immunosuppressive therapy improve symptoms and prevent recurrence in a patient with recurrent myocarditis and a DSP mutation?
Case Report (n=1)
Does immunosuppressive therapy improve symptoms and prevent recurrence in a patient with recurrent myocarditis and a DSP mutation?
This case highlights the potential utility of tailored immunosuppressive therapy, such as mycophenolate mofetil, in managing recurrent myocarditis associated with DSP mutations.
DSP variants warrant consideration in familial recurrent pediatric myocarditis; leaves open need for larger genetic studies before screening changes.
Acute myocarditis, often linked to viral infections and autoimmune processes, significantly contributes to sudden cardiac death in young adults. Recurrent episodes can result from genetic mutations, particularly involving desmosomal proteins like desmoplakin ( DSP ). An accurate genetic diagnosis is essential for proper patient management. We present a case of a 14-year-old Caucasian male with recurrent chest pain and elevated troponin. His maternal history was notable for recurrent myocarditis. Genetic testing revealed a novel DSP variant c.2917G > T p.Glu973* in heterozygosity, classified as likely pathogenic and associated with cardiomyopathy, woolly hair, keratoderma, and tooth agenesis (MIM: 615821 ). Initial treatment with colchicine, prednisolone, and azathioprine managed to control symptoms but failed to prevent recurrence. Mycophenolate mofetil was later introduced, leading to a more sustained improvement. Recent literature linked DSP mutations to cardiomyopathies with high risks of arrhythmias and heart failure. While current management focuses on optimizing the underlying cardiovascular hemodynamic burden, this case highlights the potential utility of immunosuppressive therapy. Further research is needed to clarify its role in modifying disease progression. DSP mutations should be considered in recurrent myocarditis. Early molecular diagnosis and tailored immunosuppressive strategies may help mitigate fibrosis and improve long-term outcomes. • Recognizing the importance of conducting genetic testing in cases of recurrent myocarditis • Highlighting the value of family history assessment in cases of recurrent myocarditis • Appreciating the role of cardiac MRI in evaluating myocarditis patients • Acknowledging the limited understanding regarding preventive measures for recurrent myocarditis
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2024) conducted a case report in Recurrent myocarditis (n=1). DSP variant c.2917G > T p.Glu973 was evaluated. A novel DSP variant (c.2917G > T p.Glu973) was identified as the cause of recurrent myocarditis in a 14-year-old male, with symptoms eventually controlled by mycophenolate mofetil.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: